AzTrials
AzTrials

Prostate CancerPRODUCANNCT03572621

Development and Evaluation of a Therapeutic Education Intervention in Prostate Cancer Patients Treated With Radical Prostatectomy to Improve Their Sexuality

A study testing Therapeutic education, Collection of data concerning their sexuality and Participation in people with Prostate Cancer, run by Hospices Civils de Lyon at 2 sites in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Prostate cancer is the most common cancer in France (54,000 cases in 2011). About 20,000 radical prostatectomies (PR) per year are performed. Despite the progress of PR over the past 20 years, the rate of erectile dysfunction post PR varies between 30 and 90% and only 16% of operated men recover their pre-treatment… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Prostate Cancer
What is being tested?
Therapeutic education, Collection of data concerning their sexuality and Participation
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
240 participants
Where
2 sitesFrance
Study dates
3 Feb 2020to Sep 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Patients treated in urology consultation at the University Hospital of Lyon Sud or Edouard Herriot:
  • Aged over 18
  • presenting a cancerous pathology of the prostate having an indication of radical prostatectomy with or without preservation of the neurovascular strips.
  • affiliated to a social security scheme.
  • and having been informed and given informed consent to participation in the program.

Who cannot join

  • Refusal of participation, signature of consent,
  • protected major patients, under guardianship or curators.
  • Patients unable to understand the course of the study
  • Patient with a documented history of cognitive or psychiatric disorders.

Trial locations and contacts

2 sites in 1 country.

France2 sites, 2 recruiting
  • Hôpital Hédouard Herriot

    Lyon, 69003

    CUZIN Béatrice, MD

    Béatrice CUZIN, MD

    Recruiting
  • Centre Hospitalier Lyon Sud

    Pierre-Bénite

    Damien CARNICELLI, MD, damien.carnicelli@chu-lyon.fr

    Damien CARNICELLI, MD

    Recruiting

Other trials in France

About this study

Prostate cancer is the most common cancer in France (54,000 cases in 2011). About 20,000 radical prostatectomies (PR) per year are performed. Despite the progress of PR over the past 20 years, the rate of erectile dysfunction post PR varies between 30 and 90% and only 16% of operated men recover their pre-treatment erections.

There is currently no validated post-prostatectomy rehabilitation protocol. The associations of patients, including the National Association of Prostate Cancer Patients have a very strong demand for treatment of sexual problems after treatment.

Conditions
Prostate Cancer
Being tested
Therapeutic education, Collection of data concerning their sexuality, Participation
Keywords
Prostatectomy
Medical subject headings
Prostatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Therapeutic educationOther

    Patients will benefit from the first session of preoperative therapeutic education, then the next 5 sessions will be done postoperatively over a period of 4 month and a half.

    Session 1: The first session will be devoted appropriately to patient education. It will take place on the day of the preoperative anesthesia consultation.

    Session 2: day of discharge from hospital. Make the patient adhere to the concept of post PR erectile rehabilitation in the same way as sphincter reeducation.

    Session 3: Presentation of available treatments, start intracavernous injections.

    Session 4: Acquisition of know-how on treatment management. Reduce anxiety. Session 5: Encourage the resumption of intercourse very gradually. The presence of the partner will be advised.

    Session 6: measure of the evolution of the representations and knowledge of the patient. The skills of the patient will be evaluated from problem situations, motivation scale. The know-how will be evaluated using observation grid.

  • Collection of data concerning their sexualityOther

    Patients in the control group are offered to participate in the study, which consists of collecting data on their sexuality. This in addition to the current care by the teams of care about erectile rehabilitation (information and medication prescriptions).

  • ParticipationOther

    Participation in a therapeutic education day.

Study groups in NCT03572621
Study groupRoleWhat they receive
Experimental groupExperimentalPatients in the experimental group are offered to participate in a 6-session therapeutic education program on sexuality, ranging from 15 days before surgery to approximately 3 months after. This in addition to the current care by the teams of care about sexual rehabilitation (information and medication prescriptions).
Receives: Other: Therapeutic education
Control groupSham comparatorPatient without therapeutic education.
Receives: Other: Collection of data concerning their sexuality
PartnerOtherPatient's partner.
Receives: Other: Participation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change the quality of sexual life of patients treated with radical prostatectomy (PR)

    Comparison of the difference in self-Esteem quotation and Relationship (SEAR) questionnaire, between the experimental group and control, between inclusion and Month 18.

    Measured: 18 months

Secondary outcomes (14)
  1. Sexual function

    Measure of The International Index of Erectile Function (IIEF-EF) score. This validated score measures the erectile component.

    Measured: Month 1, 6, 12 and 18

  2. General quality of life

    Signing of questionnaire EuroQol-D5 (EQ-D5)

    Measured: Month 1, 6, 12 and 18

  3. Sexual quality of life of the partner

    Index of Sexual Life (ISL) questionnaire, validated questionnaire specifically created to assess the impact of erectile dysfunction (ED) in the partner.

    Measured: Month 1, 6, 12 and 18

  4. Number of erections obtained in the last month

    Patient questionnaire to be filled every month at home by the patient and the partner

    Measured: Month 1, 6, 12 and 18

  5. Number of reports deemed satisfactory

    Patient questionnaire to be filled every month at home by the patient and the partner

    Measured: Month 1, 6, 12 and 18

  6. Number of intracavernous injections performed per week

    Patient questionnaire to be filled every month at home by the patient and the partner

    Measured: Month18

  7. Patient Activation Measure (questionnaire PAM)

    Measured: Month18

  8. Erection Hardness Score (EHS)

    Measured: Month 1, 6, 12 and 18

  9. Continence: urinary handicap measurement scale (MHU)

    Measured: Month 1, 6, 12 and 18

  10. Penis size (cm)

    Measured: Month 1, 6, 12 and 18

  11. Knowledge acquisition measured by quizz build for the study made of simulated cases

    Measured: Month 1, 6, 12 and 18

  12. acquisition of sexual intercourse management skills measured by quizz build for the study made of simulated cases

    Measured: Month 1, 6, 12 and 18

  13. Anxiety level measured by the Hospital Anxiety and Depression (HAD) scale

    Measured: Month 6 and18

  14. Depression level measured by the Hospital Anxiety and Depression (HAD) scale

    Measured: Month 6 and18

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jun 2018
  2. Study start3 Feb 2020
  3. Primary completionFeb 2023 (estimated)
  4. Study completionSep 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
240 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03572621
Sponsor's protocol ID
69HCL17_0010
Acronym
PRODUCAN
Status last verified
Mar 2022
First submitted
4 Jun 2018
Last updated
7 Mar 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Therapeutic education, Collection of data concerning their sexuality and Participation in people with Prostate Cancer, run by Hospices Civils de Lyon at 2 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 7 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Damien CARNICELLI, MD (04 72 67 88 01 ext. +33, damien.carnicelli@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change the quality of sexual life of patients treated with radical prostatectomy (PR) (time frame: 18 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in